{"id":386760,"date":"2017-04-10T00:00:00","date_gmt":"2017-04-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360ha0008-medtech-hyaluronic-acid-viscosupplementation-global-2017-market-analysis\/"},"modified":"2026-05-07T11:07:08","modified_gmt":"2026-05-07T11:07:08","slug":"m360ha0008-medtech-hyaluronic-acid-viscosupplementation-global-2017-market-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360ha0008-medtech-hyaluronic-acid-viscosupplementation-global-2017-market-analysis\/","title":{"rendered":"Hyaluronic Acid Viscosupplementation | Global | 2017 | Market Analysis"},"content":{"rendered":"<p>The global market for\u00a0<abbr title=\"Hyaluronic Acid\">HA<\/abbr>\u00a0viscosupplementation will exhibit moderate growth through 2025, driven by rising use of this treatment, especially in the Asia Pacific region. While premium-priced 1-injection products will continue to become more popular over the forecast period, 3- and 5-injection products will retain their dominance in some countries due to differences in product access and reimbursement, and because there is more clinical data supporting the efficacy of these products.\u00a0<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for the US, Europe, Asia Pacific, and Brazil\u00a0across a 10-year period.<\/p>\n<p>\u00a0<\/p>\n<p><strong>The continuing introduction of products and expanded indications in the\u00a0<abbr title=\"Hyaluronic Acid\">HA<\/abbr>\u00a0viscosupplementation market will drive market growth.<\/strong><\/p>\n<p>How will the introduction of new products help offset the negative recommendation against\u00a0<abbr title=\"Hyaluronic Acid\">HA<\/abbr>\u00a0injections by the\u00a0<abbr title=\"American Academy of Orthopaedic Surgeons\">AAOS<\/abbr>\u00a0in the US?<\/p>\n<p>How quickly will the nonknee market segment expand in the US following the anticipated approval of these indications?<\/p>\n<p><strong>Reimbursement for\u00a0<abbr title=\"Hyaluronic Acid\">HA<\/abbr>\u00a0injections is facing greater scrutiny in Europe.<\/strong><\/p>\n<p>Which countries have limited or a complete lack of reimbursement for these products?<\/p>\n<p>In France, what reimbursement changes have occurred and what decisions are still pending? What strategies can companies use to promote their products when reimbursement is lacking?<\/p>\n<p><strong>In the Asia Pacific region and Brazil, domestic manufacturers have gained market share.<\/strong><\/p>\n<p>How are domestic manufacturers&#8217; product offerings evolving?<\/p>\n<p>In which countries do domestic companies hold particularly high market shares and why?\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-386760","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-date-889"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386760\/revisions"}],"predecessor-version":[{"id":388257,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386760\/revisions\/388257"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=386760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}